本研究将探讨以glofitamab为基础的治疗在复发性或难治性扩散性大B细胞淋巴瘤(R/R DLBCL)的中国成人参与者中的有效性和安全性。
适应症：Diffuse Large B-Cell Lymphoma
入组条件
纳入标准
- Histologically confirmed R/R DLBCL after one line of systemic therapy
- Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment
排除标准
- Participants who currently participate in or plan to participate in any interventional clinical trial
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。